Overview
Mark Dorreen practices practicing medicine in Halifax, Canada.
His clinical expertise encompasses Febrile Neutropenia, HER-2 Positive Breast Cancer, and Pancreatic Cancer.
He is actively involved in clinical research, co-authoring 9 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Mark S. Dorreen
Is Mark S. Dorreen a top-rated expert for Febrile Neutropenia?
MediFind is an objective health platform that identifies experts based on real-world data. Mark S. Dorreen is classified as an Experienced expert for Febrile Neutropenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Mark S. Dorreen participate in research or clinical trials?
Yes. Mark S. Dorreen has published 9 articles and abstracts on conditions like Febrile Neutropenia. You can view a list of Mark S. Dorreen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Febrile NeutropeniaMr. Dorreen isExperienced. Learn about Febrile Neutropenia.
- HER-2 Positive Breast CancerMr. Dorreen isExperienced. Learn about HER-2 Positive Breast Cancer.
- Pancreatic CancerMr. Dorreen isExperienced. Learn about Pancreatic Cancer.